Generic Tyvaso Availability
Last updated on Apr 10, 2025.
See also: Generic Tyvaso DPI
Tyvaso is a brand name of treprostinil, approved by the FDA in the following formulation(s):
TYVASO (treprostinil - solution;inhalation)
-
Manufacturer: UNITED THERAP
Approval date: July 30, 2009
Strength(s): 0.6MG/ML [RLD]
Is there a generic version of Tyvaso available?
No. There is currently no therapeutically equivalent version of Tyvaso available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tyvaso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Treprostinil administration by inhalation
Patent 10,376,525
Issued: August 13, 2019
Inventor(s): Olschewski Horst & Roscigno Robert & Rubin Lewis J. & Schmehl Thomas & Seeger Werner & Sterritt Carl & Voswinckel Robert
Assignee(s): United Therapeutics CorporationTreprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
Patent expiration dates:
- May 14, 2027✓
- May 14, 2027
-
Process to prepare treprostinil, the active ingredient in Remodulin®
Patent 11,723,887
Issued: August 15, 2023
Inventor(s): Batra; Hitesh et al.
Assignee(s): United Therapeutics Corporation (Silver Spring, MD)This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Patent expiration dates:
- December 15, 2028✓
- December 15, 2028
-
Treatment for interstitial lung disease
Patent 11,826,327
Issued: November 28, 2023
Inventor(s): Peterson; Leigh et al.
Assignee(s): United Therapeutics Corporation (Silver Spring, MD)Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
Patent expiration dates:
- February 3, 2042✓
- February 3, 2042
-
Treprostinil administration by inhalation
Patent 9,339,507
Issued: May 17, 2016
Inventor(s): Olschewski Horst & Roscigno Robert & Rubin Lewis J. & Schmehl Thomas & Seeger Werner & Sterritt Carl & Voswinckel Robert
Assignee(s): United Therapeutics CorporationTreprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
Patent expiration dates:
- March 10, 2028✓
- March 10, 2028
-
Treprostinil administration by inhalation
Patent 9,358,240
Issued: June 7, 2016
Inventor(s): Olschewski Horst & Roscigno Robert & Rubin Lewis J. & Schmehl Thomas & Seeger Werner & Sterritt Carl & Voswinckel Robert
Assignee(s): United Therapeutics CorporationTreprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
Patent expiration dates:
- May 5, 2028✓
- May 5, 2028
-
Process to prepare treprostinil, the active ingredient in remodulin®
Patent 9,593,066
Issued: March 14, 2017
Inventor(s): Batra Hitesh & Tuladhar Sudersan M. & Penmasta Raju & Walsh David A.
Assignee(s): United Therapeutics CorporationThis present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Patent expiration dates:
- December 15, 2028✓
- December 15, 2028
More about Tyvaso (treprostinil)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (18)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: agents for pulmonary hypertension
- Breastfeeding
Patient resources
Other brands
Remodulin, Tyvaso DPI, Orenitram
Professional resources
Other brands
Remodulin, Tyvaso DPI, Orenitram
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.